Business Context and Reporting Period
Company: Organogenesis Holdings Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 9, 2020
Reporting Period: Fiscal fourth quarter and full year ended December 31, 2019.
This filing serves to announce the Company's financial results for the fourth quarter and fiscal year 2019 and to introduce revenue guidance for fiscal year 2020. The filing incorporates a press release (Exhibit 99.1) and a corporate presentation (Exhibit 99.2) by reference.
Key Financial Metrics
The Form 8-K text itself does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are detailed in the press release attached as Exhibit 99.1, which is incorporated by reference but not reproduced in the provided text.
Material Changes
The filing indicates the announcement of results for the fiscal fourth quarter and year ended December 31, 2019. Specific material changes compared to prior periods are not quantified in the 8-K text and are contained within the referenced press release.
Guidance, Outlook, and Management Commentary
- Guidance: The Company introduced revenue guidance for fiscal year 2020 in the press release dated March 9, 2020.
- Management Commentary: The Company provides summary business information through a corporate presentation (Exhibit 99.2) used at industry conferences.
- Disclaimer: The Company explicitly disclaims any obligation to correct or update the information in the corporate presentation in the future.
- Legal Status of Exhibits: The press release and corporate presentation are furnished, not "filed," for purposes of Section 18 of the Exchange Act, and are not subject to the liabilities of that section unless expressly incorporated by reference in another filing.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q4 and full-year 2019 revenue, net income, and cash flow figures.
- Verify the specific revenue guidance range provided for fiscal year 2020 in the press release.
- Examine Exhibit 99.2 (Corporate Presentation) for strategic updates, noting the disclaimer regarding future updates.
- Confirm the trading symbol (ORGO) and exchange (Nasdaq Capital Market) for Class A Common Stock.